The synthesis and characterization of a series of new cyclometalated iridium(III) complexes [Ir(ppy)₂(N∧N)][PF₆] in which Hppy = 2-phenylpyridine and N∧N is (pyridin-2-yl)benzo[d]thiazole (L1), 2-(4-(tert-butyl)pyridin-2-yl)benzo[d]thiazole (L2), 2-(6-phenylpyridin-2-yl)benzo[d]thiazole (L3), 2-(4-(tert-butyl)-6-phenylpyridin-2-yl)benzo[d]thiazole (L4), 2,6-bis(benzo[d]thiazol-2-yl)pyridine (L5), 2-(pyridin-2-yl)benzo[d]oxazole (L6), or 2,2'-dibenzo[d]thiazole (L7) are reported. The single crystal structures of [Ir(ppy)₂(L1)][PF₆]·1.5CH₂Cl₂, [Ir(ppy)₂(L6)][PF₆]·CH₂Cl₂, and [Ir(ppy)₂(L7)][PF₆] have been determined. The new complexes are efficient red emitters and have been used in the active layers in light-emitting electrochemical cells (LECs). The effects of modifications of the 2-(pyridin-2-yl)benzo[d]thiazole ligand on the photoluminescence and LEC performance have been examined. Extremely stable red-emitting LECs are obtained, and when [Ir(ppy)₂(L1)][PF₆], [Ir(ppy)₂(L2)][PF₆], or [Ir(ppy)₂(L3)][PF₆] are used in the active layer, device lifetimes greater than 1000, 6000, and 4000 h, respectively, are observed.
No takes yet. Share an insight, caveat, or question.
Ertl et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: